TMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

CONCERNING A FILING UNDER 35 U.S.C. 371

217550US0PCT

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

10/031371

INTERNATIONAL APPLICATION NO.
PCT/EP00/06545

INTERNATIONAL FILING DATE
10 JULY 2000

PRIORITY DATE CLAIMED

19 JULY 1999

TTORNEY'S DOCKET NUMBER

TITLE OF INVENTION

SYNERGISTIC COMPOSITION COMPRISING DAUNORUBICIN DERIVATIVES AND ANTIMETABOLITE COMPOUNDS

APPLICANT(S) FOR DO/EO/US			
·			

Mar	ia C.	GERONI, et al.
Appli	icant l	nerewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:
1.	⊠.	This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.
2.		This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.
3.	Ø	This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include itens (5), (6), (9) and (24) indicated below.
4.	\boxtimes	The US has been elected by the expiration of 19 months from the priority date (Article 31).
5.	\boxtimes	A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
		a. is attached hereto (required only if not communicated by the International Bureau).
		b. 🛮 has been communicated by the International Bureau.
		c. is not required, as the application was filed in the United States Receiving Office (RO/US).
6.		An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
		a. is attached hereto.
		b. has been previously submitted under 35 U.S.C. 154(d)(4).
7.	\boxtimes	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
		a. are attached hereto (required only if not communicated by the International Bureau).
		b. have been communicated by the International Bureau.
		c. have not been made; however, the time limit for making such amendments has NOT expired.
		d. 🛮 have not been made and will not be made.
8.		An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9.		An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
10.		An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
11.	\boxtimes	A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12.	\boxtimes	A copy of the International Search Report (PCT/ISA/210).
It	ems 1	3 to 20 below concern document(s) or information included:
13.	\boxtimes	An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14.		An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15.	\boxtimes	A FIRST preliminary amendment.
16.		A SECOND or SUBSEQUENT preliminary amendment.
17.		A substitute specification.
18.		A change of power of attorney and/or address letter.
19.		A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
20.		A second copy of the published international application under 35 U.S.C. 154(d)(4).

21.

A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).

23.

Other items or information:

Notice of Priority / PCT/IB/304 / PCT/IB/308 PTO-1449

U.S. A	PPLICA	TIONN	O. (IF KNO	31 ^{set}	379	INTERNATIONAL A PCT/E	applicat P00/065 4		NO.		ATTORNEY'S I 217550	DOCKET NUN USOPCT	⊿BER
24.	Т	he follo	wing fees	are subn	nitted:.				*	CAL	CULATIONS	PTO USE O	ONLY
BASIC	Neithe	r intern	ational pre	liminary 37 CFR	1.445(a)(2))	(5)): n fee (37 CFR 1.482) n paid to USPTO by the EPO or JPO			\$1040.00				
·	Interna	itional r	oreliminary	examin	ation fee (37	CFR 1.482) not paid ared by the EPO or JP	to		\$890.00				
. 🗆	Interna	itional r	oreliminary	examin	ation fee (37	CFR 1.482) not paid (2)) paid to USPTO.	to USPTO	O	\$740.00				
	Interna	itional r	reliminary	examin	ation fee (37	CFR 1.482) paid to UT Article 33(1)-(4)	JSPTO		\$710.00				
	Interna	tional p	oreliminary satisfied p	examin	ation fee (37 s of PCT An	CFR 1.482) paid to Uticle 33(1)-(4)	JSPTO 		\$100.00				
			ENTE	R AP	PROPRI.	ATE BASIC FE	EE AM	OU:	NT =		\$890.00		
Surcha month	rge of S s from t	130.00 he earli	for furnishest claimed	ning the I priority	oath or decla date (37 Cl	ration later than FR 1.492 (e)).	□ 2	0	⊠ 30		\$130.00		
CL.	AIMS		NUI	MBER F	FILED	NUMBER EXT	RA		RATE	ļ <u>.</u>			
Total c	laims			13	- 20 =	0		х	\$18.00	ļ	\$0.00		
Indepe	ndent c	laims		_1	- 3=	0		х	\$84.00		\$0.00		
Multip	le Depe	ndent C	Claims (che							ļ	\$0.00		
						ABOVE CALO				<u> </u>	\$1,020.00		
	pplican educed		s small enti	ty status	s. See 37 CF	R 1.27). The fees indic	cated abov	ve are			\$0.00		
			·				SUB'	TO'	$\Gamma AL =$	ļ	\$1,020.00		
Proces month:	sing fee s from t	of \$13 he earli	0.00 for fur est claimed	rnishing I priority	the English date (37 Cl	translation later than FR 1.492 (f)).	☐ 2 ¹	0	□ 30 +		\$0.00		
						TOTAL NAT	IONA	L F	EE =		\$1,020.00		
Fee for	r record panied l	ing the	enclosed as	ssignmer cover she	nt (37 CFR 1 eet (37 CFR	.21(h)). The assignm 3.28, 3.31) (check if	ent must l	be le).			\$0.00		
		-	-			TOTAL FEES	ENCL	OS	ED =		\$1,020.00		
		·								Amou	int to be: efunded	\$	
1											harged	\$	
a.	×		ck in the an										
b.				-	t Account No sheet is enclo		in the am	ount	of	<u> </u>	to cover th	e above fees.	
c.	\boxtimes		ommission osit Accou			ed to charge any addit A duplicate co					or credit any o	verpayment	
d.		Fees a	re to be cha	arged to	a credit card be included	. WARNING: Inform on this form. Provide	nation on i	this f ard in	orm may bed formation an	ome pu	blic. Credit ca	ard O-2038.	
		re an a _l	ppropriate	time lir	nit under 31	7 CFR 1.494 or 1.495	has not	been	met, a petit				
	,		PONDEN	_		the application to	ponome c			1			
SEND	ALLC	OKKES	FONDEN	CE TO.]	SI	Juli GNATURE	vdn_	Sachar		
			112811241-41-41		(IIII 441 4 15			NI.	orman F. C	hlen			
									AME		•		
			11881181181		1011 88 11 1 88 1								
			2	285	0		1		,618				
					Surinde	r Sachar	1	. RE	EGISTRATIO	טא אט.			
(703)	413-30	DO		Re		No. 34,423		DA	Ta ATE	<u>~ 1</u>	8 2002		<u> </u>
							1						

Docket No.

217550US0PCT

IN RE APPLICATION OF: Maria C. GERONI, et al.

SERIAL NO:

NEW U.S. PCT APPLICATION BASED ON PCT/EP00/06545

FILED:

HEREWITH

SYNERGISTIC COMPOSITION COMPRISING DAUNORUBICIN DERIVATIVES AND

FOR:

ANTIMETABOLITE COMPOUNDS

ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

SIR:

Transmitted herewith is an amendment in the above-identified application.

No additional fee is required

Small entity status of this application under 37 C.F.R. §1.9 and §1.27 is claimed.

Additional documents filed herewith:

Preliminary Amendment/Notice of Priority/PCT/IB/304/PCT Transmittal Letter PCT/IB/308/International Search Report/Information Disclosure Statement International Preliminary Examination Report/PTO-1449/Check for \$1,020.00

The Fee has been calculated as shown below:

CLAIMS	CLAIMS REMAINING		HIGHEST NUMBER PREVIOUSLY PAID	NO. EXTRA CLAIMS		RATE		CALCULATIONS
TOTAL	13	MINUS	20	0	×	\$18	=	\$0.00
INDEPENDENT	1	MINUS	3	0	×	\$84	=	\$0.00
		☐ MULT	IPLE DEPENDENT (CLAIMS	+	\$280	=	\$0.00
		TOTAL OF ABOVE CALCULATIONS						\$0.00
		☐ Reduct	ion by 50% for filing	by Small Entity	У			\$0.00
		Record	ation of Assignment		+	\$40	=	\$0.00
						TOTA	٩L	\$0.00

☐ A check in the amount of \$0.00 is attached.

- Please charge any additional Fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit Account No. 15-0030. A duplicate copy of this sheet is enclosed.
- 🖾 If these papers are not considered timely filed by the Patent and Trademark Office, then a petition is hereby made under 37 C.F.R. §1.136, and any additional fees required under 37 C.F.R. §1.136 for any necessary extension of time may be charged to Deposit Account No. 15-0030. A duplicate copy of this sheet is enclosed.

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No. 24,618

Surinder Sachar

Registration No. 34,423

Customer Number 22850 Tel. (703) 413-3000

Fax. (703) 413-2220 (OSMMN 10/01)

JC13 Pec'd PCT/PTO 18 JAN 2002



DOCKET NO.: 217550 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Maria C. GERONI, et al.

SERIAL NO.: NEW U.S. PCT APPLICATION

FILED: HEREWITH

INTERNATIONAL APPLICATION NO.: PCT/EP00/06545

INTERNATIONAL FILING DATE: July 10, 2000

FOR: SYNERGISTIC COMPOSITION COMPRISING DAUNORUBICIN DERIVATIVES AND

ANTIMETABOLITE COMPOUNDS

REQUEST FOR PRIORITY UNDER 35 U.S.C. 119 AND THE INTERNATIONAL CONVENTION

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In the matter of the above-identified application for patent, notice is hereby given that the applicant claims as priority:

COUNTRY

APPLICATION NO

DAY/MONTH/YEAR

Great Britain

9916882.5

19 July 1999

Certified copies of the corresponding Convention application(s) were submitted to the International Bureau in PCT Application No. PCT/EP00/06545. Receipt of the certified copy(s) by the International Bureau in a timely manner under PCT Rule 17.1(a) has been acknowledged as evidenced by the attached PCT/IB/304.

Respectfully submitted, OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon

Attorney of Record

Registration No. 24,618

Surinder Sachar

Registration No. 34,423

22850

(703) 413-3000 Fax No. (703) 413-2220 (OSMMN 1/97)